Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus gemcitabine and cisplatin for muscle-invasive bladder urothelial carcinoma
ChiCTR2000037670Phase 4Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in transitional cell carcinoma of the bladder (TCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathologic complete response rate. Started Sep 2020; status: completed.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2000037670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037670.